The Casein Kinase I Isoform Delta pipeline drugs market research report outlays comprehensive information on the Casein Kinase I Isoform Delta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Casein Kinase I Isoform Delta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Central Nervous System, Musculoskeletal Disorders, and Respiratory which include the indications Breast Cancer, Colorectal Cancer, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Fibrosis, and Idiopathic Pulmonary Fibrosis. It also reviews key players involved in Casein Kinase I Isoform Delta targeted therapeutics development with respective active and dormant or discontinued products.

The Casein Kinase I Isoform Delta pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 5, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Casein Kinase I Isoform Delta overview

Casein Kinase I Isoform Delta plays a vital role in regulating various cellular processes related to growth and survival, encompassing Wnt signaling, DNA repair, and circadian rhythms. It exhibits the capability to phosphorylate a diverse array of proteins. Casein kinases are characterized by their operational preference for acidic proteins like caseins as substrates. It engages in the phosphorylation of numerous proteins, including connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1, and PER2. It holds a central role in the circadian clock, influencing the circadian period length by regulating the speed and rhythmicity of PER1 and PER2 phosphorylation in collaboration with PP1. It governs the nuclear transport and degradation of PER1 and PER2, while YAP1 phosphorylation facilitates its ubiquitination and degradation through SCF(beta-TRCP) E3 ubiquitin ligase. DNMT1 phosphorylation diminishes its DNA-binding activity. The phosphorylation of ESR1 and AIB1/NCOA3 enhances their activity and coactivation. Moreover, the phosphorylation of DVL2 and DVL3 regulates the WNT3A signaling pathway, influencing neurite outgrowth. This kinase also plays a role in phosphorylating NEDD9/HEF1.

For a complete picture of Casein Kinase I Isoform Delta’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.